Qiagen's Revenues Rise 22 Percent in Q4, Eclipse $1B Mark for FY 2009

Qiagen's revenues were driven by its molecular diagnostics sales, which now account for nearly 50 percent of the firm's total sales.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories